Q1 2025 Management View CEO John Oyler highlighted the company’s progress in achieving GAAP profitability in Q1 2025 for the ...

BeiGene posted a surprise Q1 profit and $1.12 billion in revenue, with strong U.S. Brukinsa sales, while reaffirming its 2025 ...

Sino American biotech BeiGene (Nasdaq: ONC; HKEX: 06160), a global oncology company that will change its name to BeOne ...

The headline numbers for BeiGene (ONC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates ...

BeiGene Ltd ( ($HK:6160) ) has shared an announcement. BeiGene, Ltd. has released its quarterly report for the period ending March 31, 2025, filed ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the ...

In January 2023, the Brukinsa, a next-generation BTK inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL).

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

A tribunal within the US Patent and Trademark Office invalidated several claims of a patent held by AbbVie’s Pharmacyclics, ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a ...

Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside ...

Limited’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.